erlotinib hydrochloride has been researched along with Sycosis in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Acquitter, M; Chiappa, AM; Dervout, C; Fleuret, C; Plantin, P | 1 |
| Botella-Estrada, R; Escutia-Muñoz, B; Rodríguez-Serna, M; Sahuquillo-Torralba, A | 1 |
| Keith, DJ; Stewart, DG | 1 |
| Dika, E; Patrizi, A | 1 |
| Castillo, C; Collet-Benzaquen, D; Combemale, P; de la Fouchardière, A; Desseigne, F; Fattouh, K; Provensal, AM | 1 |
| Acharya, J; Bottomley, DM; Lyon, C | 1 |
| Brown, CW; Campbell, TM | 1 |
| Aractingi, S; Nassar, D; Soutou, B | 1 |
| Drillenburg, P; Hoekzema, R | 1 |
| Becker, A; Postmus, PE; Smit, EF; van Wijk, A | 1 |
| Aguilar, A; Aspiroz, C; Cuétara, MS; del Palacio, A; Martin, L | 1 |
| Gerdes, S; Mrowietz, U | 1 |
| Al Hammadi, A; Gerstein, W; Tangri, N | 1 |
| Nguyen, D; Parr, AL; Steinberg, SM; Tan, AR; Yang, SX | 1 |
1 trial(s) available for erlotinib hydrochloride and Sycosis
| Article | Year |
|---|---|
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Topics: Acneiform Eruptions; Antineoplastic Agents; Biomarkers; Biopsy; Breast Neoplasms; Carcinoma; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gene Expression Profiling; Humans; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin | 2008 |
13 other study(ies) available for erlotinib hydrochloride and Sycosis
| Article | Year |
|---|---|
[Erlotinib-induced scarring alopecia with a folliculitis decalvans-like presentation].
Topics: Alopecia; Cicatrix; Erlotinib Hydrochloride; Erythema; Female; Folliculitis; Humans; Middle Aged; Neoplasm Recurrence, Local | 2020 |
Folliculitis Decalvans Caused by Bacterial Superinfection Secondary to Erlotinib.
Topics: Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Fatal Outcome; Female; Folliculitis; Humans; Staphylococcal Infections; Staphylococcus aureus; Superinfection | 2018 |
Erlotinib-induced folliculitis decalvans.
Topics: Aged; Anti-Infective Agents; Drug Therapy, Combination; Erlotinib Hydrochloride; Folliculitis; Glucocorticoids; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Prevention of erlotinib-induced folliculitis with doxycycline.
Topics: Doxycycline; Erlotinib Hydrochloride; Folliculitis; Humans; Protein Kinase Inhibitors | 2017 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Eruptions; Erlotinib Hydrochloride; Fluorouracil; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male | 2017 |
Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2009 |
Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Topics: Acneiform Eruptions; Aged; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Male; Protein Kinase Inhibitors; Psoriasis; Quinazolines | 2008 |
[Cutaneous side effects of EGF receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gefitinib; Humans; Nail Diseases; Panitumumab; Quinazolines; Skin | 2009 |
Folliculitis decalvans associated with erlotinib.
Topics: Alopecia; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Folliculitis; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Staphylococcus aureus | 2010 |
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Folliculitis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2010 |
Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis.
Topics: Aged; Antineoplastic Agents; Dermatomycoses; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Malassezia; Male; Quinazolines; Rosacea | 2006 |
Follicular rash during therapy with erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Facial Dermatoses; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2006 |
Epidermal growth factor receptor inhibitor-related folliculitis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Face; Folliculitis; Humans; Lung Neoplasms; Male; Neck; Protein Kinase Inhibitors; Quinazolines | 2007 |